A detailed history of Db Fitzpatrick & Co, Inc transactions in Amgen Inc stock. As of the latest transaction made, Db Fitzpatrick & Co, Inc holds 4,287 shares of AMGN stock, worth $1.37 Million. This represents 1.22% of its overall portfolio holdings.

Number of Shares
4,287
Previous 4,311 0.56%
Holding current value
$1.37 Million
Previous $1.35 Million 2.6%
% of portfolio
1.22%
Previous 1.25%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 16, 2024

SELL
$309.38 - $337.38 $7,425 - $8,097
-24 Reduced 0.56%
4,287 $1.38 Million
Q2 2024

Jul 17, 2024

BUY
$262.75 - $319.31 $671,063 - $815,517
2,554 Added 145.36%
4,311 $1.35 Million
Q1 2024

Apr 19, 2024

SELL
$268.87 - $324.56 $618,669 - $746,812
-2,301 Reduced 56.7%
1,757 $499,000
Q4 2023

Jan 23, 2024

BUY
$255.7 - $288.46 $4,858 - $5,480
19 Added 0.47%
4,058 $1.17 Million
Q3 2023

Nov 01, 2023

BUY
$218.65 - $271.46 $19,459 - $24,159
89 Added 2.25%
4,039 $1.09 Million
Q2 2023

Aug 09, 2023

SELL
$214.27 - $253.37 $38,354 - $45,353
-179 Reduced 4.34%
3,950 $876,000
Q1 2023

Apr 24, 2023

BUY
$225.79 - $275.2 $491,996 - $599,660
2,179 Added 111.74%
4,129 $998,000
Q4 2022

Jan 24, 2023

SELL
$229.03 - $291.01 $157,572 - $200,214
-688 Reduced 26.08%
1,950 $0
Q3 2022

Oct 20, 2022

SELL
$224.46 - $253.15 $59,032 - $66,578
-263 Reduced 9.07%
2,638 $595,000
Q2 2022

Jul 28, 2022

BUY
$230.71 - $256.74 $11,304 - $12,580
49 Added 1.72%
2,901 $706,000
Q1 2022

Apr 22, 2022

SELL
$219.27 - $242.57 $261,589 - $289,386
-1,193 Reduced 29.49%
2,852 $690,000
Q4 2021

Feb 03, 2022

BUY
$198.88 - $227.6 $804,469 - $920,642
4,045 New
4,045 $910,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $171B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Db Fitzpatrick & Co, Inc Portfolio

Follow Db Fitzpatrick & Co, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Db Fitzpatrick & Co, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Db Fitzpatrick & Co, Inc with notifications on news.